Accidental intralenticular sustained-release dexamethasone (Ozurdex) implantation: A case report

Authors

  • Chaitali Basu
  • Rakesh Jha

DOI:

https://doi.org/10.32677/ijcr.v7i8.2996

Keywords:

Intralenticular implantation, Intravitreal, Ozurdex, Posterior subcapsular cataract

Abstract

Intravitreal implantation of Ozurdex (Allergan Inc., Irvine, CA, USA), a sustained-release dexamethasone implant, is a common practice in ophthalmology. Inadvertent intralenticular implantation of Ozurdex is a very rare complication. Herein, we report a case of accidental intralenticular Ozurdex implantation. During the intravitreal procedure, the patient moved his head vigorously which resulted in the said complication. He was followed up periodically with monitoring of intraocular pressure (IOP), best-corrected visual acuity, lens status, fundus, and macular edema status. He developed a posterior subcapsular cataract after about 5 months of the procedure. The cataract was removed around 6 months follow-up by phacoemulsification with anterior vitrectomy and implantation of a 3-piece posterior chamber intraocular lens in the ciliary sulcus. Macular edema had resolved by 3 months of Ozurdex implantation and the patient did not require a second intravitreal dose. He was well at 3 months follow up after cataract surgery.

Downloads

Download data is not yet available.

Downloads

Published

2021-08-28

Issue

Section

Case Report

How to Cite

Accidental intralenticular sustained-release dexamethasone (Ozurdex) implantation: A case report. (2021). Indian Journal of Case Reports, 7(8), 360-362. https://doi.org/10.32677/ijcr.v7i8.2996

Most read articles by the same author(s)

<< < 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 > >>